Comparison of the Efficacy and Safety of Entecavir Versus Adefovir in Subjects Chronically Infected With Hepatitis B Virus and Evidence of Hepatic Decompensation
Comparison of the Efficacy and Safety of Entecavir Versus Adefovir in Subjects Chronically Infected With Hepatitis B Virus and Evidence of Hepatic Decompensation
This is a phase IIIb comparative study of entecavir 1.0 mg once daily (QD) vs. adefovir 10 mg QD in patients who have chronic hepatitis B infection and hepatic decompensation. The patients are treated for 96 weeks after the last subject is randomized.
Inclusion
Exclusion
Porto Alegre - Rs, Rio Grande do Sul 90035-003, Brazil
Sao Paulo - Sp, São Paulo 05403-900, Brazil
Hyderabad, Andhra Pradesh 500082, India
Tianan, 704, Taiwan